|本期目录/Table of Contents|

[1]禹 乐综述,余英豪审校.RGC32在肿瘤中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):71-75.[doi:10.3969/j.issn.1672-271X.2020.01.016]
　YU Le reviewing,YU Ying-hao checking.Research progress of RGC32 in tumor[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):71-75.[doi:10.3969/j.issn.1672-271X.2020.01.016]
点击复制

RGC32在肿瘤中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年01期
页码:
71-75
栏目:
综述
出版日期:
2020-01-06

文章信息/Info

Title:
Research progress of RGC32 in tumor
作者:
禹 乐综述; 余英豪审校
作者单位：363000 漳州，联勤保障部队第九〇九医院病理科（禹 乐）；350025 福州，福建医科大学福总临床学院（联勤保障部队第九〇〇医院）病理科（余英豪）
Author(s):
YU Le1 reviewing;  YU Ying-hao2 checking
(1.Department of Pathology, the 909th Hospital of Joint Logistics Support Force, Zhangzhou 363000, Fujian,China; 2.Department of Pathology, the 900th Hospital of Joint Logistics Support Force, Fuzhou 350025, Fujian,China)
关键词:
补体应答基因32; 肿瘤; 细胞增殖分化; 上皮间质转化转
Keywords:
complement response gene 32;  tumor;  cell proliferation and differentiation;  epithelial-mesenchymal transformation
分类号:
R730
DOI:
10.3969/j.issn.1672-271X.2020.01.016
文献标志码:
A
摘要:
补体应答基因32（RGC32）是一种重要的补体应答基因，同时在细胞周期调控、促进组织细胞间质转化、免疫的调节、肿瘤的转移等过程中也起到关键作用。RGC32可在多种正常组织及肿瘤中广泛表达，其异常表达具有肿瘤相关性和组织差异性，如在结直肠癌、胰腺癌、乳腺癌、胃癌、卵巢癌等多种肿瘤中具有正向调控作用，在神经胶质瘤、多发性骨髓瘤中发挥反向的调节作用，在非小细胞肺癌中既可起到抑制作用又可起到促进作用。目前关于RGC32在肿瘤中的作用尚未形成统一的观点，文章就RGC32在肿瘤中的研究进行综述。
Abstract:
Complement response gene 32 (RGC32) is an important complement response gene, which plays a key role in the regulation of cell cycle, epithelial-mesenchymal transformation, immune and tumor metastasis. RGC32 is widely expressed in a variety of normal tissues and tumors. Its abnormal expression has tumor-relevant and tissue-differentiated characteristics. For example, RGC32 has a positive regulatory role in colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, ovarian cancer and other tumors, but it has a reverse regulatory role in glioma, multiple myeloma. It can also play an inhibitory and stimulative role in non-small cell lung cancer. At present, there is no consensus on the role of RGC32 in tumors. This article reviews the research progress of RGC32 in tumors.

参考文献/References:

[1] Badea TC，Niculescu FI，Soane L，et al．Molecular cloning of RGC32, a novel gene induced by complement activation in oligodendrocyte[J].Biol Chem,1998,273 (41): 26977-26981． [2] Vlaicu SI，Cudrici C，Ito T, et al. Role of response gene to complement 32 in diseases[J]．Arch Immunol Ther Exp (Warsz),2008,56(2):115-122． [3] Cui XB, Luan JN, Chen SY. RGC-32 deficiency protects against hepatic steatosis by reducing lipogenesis[J]. J Biol Chem, 2015,290(33):20387-20395. [4] Sisi C, Xiaohan M, Amelia Y, et al. Response gene to complement 32 suppresses adipose tissue thermogenic genes through inhibiting β3-adrenergic receptor/mTORC1 signaling[J]. FASEB J, 2018, 32(9):4836-4847. [5] Brocard M, Khasnis S, Wood CD, et al. Pumilio directs deadenylation-associated translational repression of the cyclin-dependent kinase 1 activator RGC-32[J]. Nucleic Acids Res, 2018,46(7):3707-3725. [6] Lu Y, Hu XB. C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation[J]. Oncol Rep,2014,32(6):2817-2823. [7] Nishioka R, Itoh S, Gui T, et al. SNAIL induces epithelial-to-mesenchymal transition in a human pancreatic cancer cell line (BxPC3) and promotes distant metastasis and invasiveness in vivo[J]. Exp Mol Pathol, 2010, 89(2):149-157. [8] Tegla CA, Cudrici CD, Azimzadeh P, et al. Dual role of Response gene to complement-32 in multiple sclerosis[J]. Exp Mol Pathol, 2013, 94(1):17-28. [9] Vlaicu SI, Tegla CA, Cudrici CD, et al. Epigenetic modifications induced by RGC-32 in colon cancer[J]. Exp Mol Pathol, 2010, 88(1):67-76. [10] Li B, Zhou W, Tang X, et al. Response Gene to Complement-32 Promotes the Imbalance of Treg/Th17 in Patients with Dilated Cardiomyopathy[J]. Cell Physiol Biochem,2017(43):1515-1525. [11] Saigusa K, lmoto I, Tankawa C,et al. RGC32 a novel pS3 inducble gene.is located on centrosomes during mitosis and results in G2/M arrest [J]. Oncogene . 2007,26(8);1110- 1121. [12] Guo S, Philbrick MJ, An X, et al. Response gene to complement 32 (RGC-32) in endothelial cells is induced by glucose and helpful to maintain glucose homeostasis.[J]. Int J Clin Exp Med, 2014, 7(9):2541-2549. [13] Vlaicu SI, Tegla CA, Cudrici CD, et al. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer[J]. Immunol Res, 2013, 56(1):109-121. [14] 沈云琳, 钮小玲, 刘华杰，等. 转化生长因子β1 通过 Smad3 调控补体应答基因32转录的分子机制[J]. 肾脏病与透析肾移植杂志,2015,24(5):447-452. [15] Shen Y L，Liu H J，Sun L，et al. Response gene to complement 32 regulates the G2/M phase checkpoint during renal tubular epithelial cell repair[J]. Cell Mol Biol Lett，2016，21：19. [16] 徐然, 赵俊刚, 石文君. RGC32与转化生长因子β1在肺腺癌细胞增殖过程中调控关系的研究[J]. 现代肿瘤医学, 2014,22(5):1009-1011. [17] Wang XY, Li SN, Zhu HF, et al. RGC32 induces epithelial-mesenchymal transition by activating the Smad/Sip1 signaling pathway in CRC[J]. Sci Rep, 2014, 289(33):22715-22722. [18] Tang R, Zhang G, Chen SY . Response Gene to Complement 32 Protein Promotes Macrophage Phagocytosis via Activation of Protein Kinase C Pathway[J]. J Biol Chem, 2014, 289(33):22715-22722. [19] Sun C, Chen SY . RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function[J]. J Immunol, 2018, 200(8):2777-2785. [20] Cui XB, Luan JN, Dong K, et al. RGC-32 (Response Gene to Complement 32 Protein) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis[J]. Arterioscler. Thromb. Vasc, 2018, 38(4) :e36-e47. [21] Chen S, Mei X, Yin A, et al. Response gene to complement 32 suppresses adipose tissue thermogenic genes through inhibiting β3-adrenergic receptor/mTORC1 signaling.[J]. FASEB J,2018,32(9):4836-4847. [22] 汪再炎,丁百静.RGC-32在结肠癌组织中的表达及临床意义[J].临床与病理杂志,2015,35(11):1958-1961. [23] 谢英娜. 补体反应基因-32在结肠癌组织中的表达及临床意义[J]. 中国药物经济学, 2017,12(1):135-137 [24] 田杰, 徐川, 杨敏慧, 等. 补体应答基因-32过表达对SW480细胞骨架的影响[J]. 南方医科大学学报, 2011, 31(7):1179-1182. [25] Xu R, Shang C, Zhao J, et al. Knockdown of response gene to complement 32 (RGC32) induces apoptosis and inhibits cell growth, migration, and invasion in human lung cancer cells[J]. Mol Cell Biochem, 2014, 394(1-2):109-118. [26] Huang WY, Li ZG, Rus H, et al. RGC-32 Mediates Transforming Growth Factor-beta-induced Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Cells[J]. Journal of Biological Chemistry J Biol Chem, 2009, 284(14):9426-9432. [27] 石昌龙,宋永胜.染料木素抑制趋化因子受体4表达对膀胱癌T24细胞迁移和侵袭的影响机制[J].东南国防医药,2019,21(3):229-233. [28] 林斯丽，段华.上皮间质转化在子宫肌腺病重的研究进展[J].医学研究生学报,2019，32(6):642-645. [29] Zhu L，Qin H，Li PY，et al. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line Bx PC-3[J]．J Exp Clin Cancer Res，2012，31: 29. [30] 朱凤, 徐文, 谢洋洋，等. RGC32在肿瘤中的表达及其临床意义[J]. 医学与哲学(B), 2015, 36(8):60-63. [31] 朱亮,赵秋,李德民,等.过表达RGC-32对胰腺癌Bx PC-3细胞增殖、凋亡的影响[J].胃肠病学和肝病学杂志,2014,23(11):1347-1350. [32] Guzmán EA, Harmody D, Pitts T P, et al. Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products [J]. Anticancer drugs, 2016, 28(2):153-160. [33] Fujiwara M, Kanayama K, Hirokawa Y S, et al. ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo[J]. Oncol Lett, 2016, 11(4):2773-2779. [34] 毛卫霞, 韩文. 增强CT定量参数与胰腺癌病灶内增殖、侵袭基因表达量的相关性[J]. 海南医学院学报, 2017, 23(21):3025-3031. [35] Sun Q, Yao X, Ning Y, et al. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial–mesenchymal transition in lung cancer cells via the NF-κB signaling pathway[J]. Tumor Biol, 2013, 34(5):2995-3002. [36] Kim DS, Lee JY, Lee SM, et al. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer[J]. Cancer, 2011, 117(3):590-596. [37] Ebrahim EN, Mohammad H, Firoozeh R . Promoter methylation and mRNA expression of Response Gene to Complement 32 in breast Carcinoma[J]. J Cancer Epidemiol, 2016, 2016:1-6. [38] 夏祥伟,茅国新.RGC-32和ZEB1在胃癌组织中的表达[J].肿瘤基础与临床,2015,28(3): 193-197. [39] 尚超,张佳星,陈秀秀,等.RGC32基因在胃癌组织中的表达及其意义[J].山东医药,2016,56 (16):77-79. [40] 田杰,周东华,平静,等.子宫颈鳞状细胞癌及鳞状上皮内病变中RGC32的表达及临床意义 [J].实用医学,2018,34(16): 1777-1779.

相似文献/References:

[1]祝斐,黄新,陈谦学,等.神经内镜切除脑室内实质性肿瘤[J].医学研究与战创伤救治(原医学研究生学报),2013,15(02):152.
　.Department of Neurosurgery,Lushan Sanatorium of Nanjing Military Command,Jiujiang,et al.ZHU Fei1,HUANG Xin1,CHEN Qian-xue2[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(01):152.
[2]孙 标综述,李向阳校审.PIM与消化系统肿瘤[J].医学研究与战创伤救治(原医学研究生学报),2012,14(04):345.
[3]高大志,张宗军,郑 玲.颅盖骨单发肿瘤的MRI诊断[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):452.
[4]卢 杰,王玉秀,张应祥,等.全身热疗对肿瘤患者肺换气功能的影响[J].医学研究与战创伤救治(原医学研究生学报),2011,13(02):130.
　LU Jie,WANG Yu-xiu,ZHANG Ying-xiang,et al.Effect of whole body hyperthermia on pulmonary gas exchange in patients with malignant tumors[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(01):130.
[5]黄乐林,沈艳喜,李 伟,等.肿瘤全身高温疗法的20例临床麻醉管理[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):33.
　HUANG Le-lin,SHEN Yan-xi,LI Wei,et al.Anesthesia manipulation for 20 cancer patients with whole body hyperthermia[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(01):33.
[6]戴英,张南征,刘军权,等.过继性细胞免疫治疗2 500例的护理观察[J].医学研究与战创伤救治(原医学研究生学报),2009,11(05):405.
　DAI Ying,ZHANG Nan-zheng,LIU Jun-quan,et al.Nursing of 2 500 patients with adoptive cellular immunotherapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(01):405.
[7]冯萍娟,蔡丽萍,刘桂苏.超声引导下甲状腺肿瘤穿刺组织活检对良恶性 的诊断价值[J].医学研究与战创伤救治(原医学研究生学报),2008,10(01):47.
[8]黄迎娣,崔 蕾,黄利鸣综述,等.上皮间质转化与肿瘤耐药[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):624.[doi:10.3969/j.issn.1672-271X.2014.06.020]
[9]柏书博综述,王敬晗,陈贵敏审校.抑癌基因LKB1与肿瘤关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2016,18(04):408.[doi:10.3969/j.issn.1672-271X.2016.04.022]
[10]王刚会,李晓芳.认知行为干预在改善肿瘤患者PICC日常管理的知-信-行水平的效果分析[J].医学研究与战创伤救治(原医学研究生学报),2016,18(06):628.[doi:10.3969/j.issn.1672-271X.2016.06.019]
　WANG Gang-hui,LI Xiao-fang..Analysis of cognitive behavioral therapy on improving the level of knowledge-attitude-practice of daily management in cancer patients with PICC[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(01):628.[doi:10.3969/j.issn.1672-271X.2016.06.019]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2020-01-06